{"success":true,"data":{"pressRelease":{"id":"48187","rtpr_id":"nPnbrCJzVa","ticker":"LNAI","exchange":"NASDAQ","all_tickers":["LNAI"],"title":"Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration","author":"PR Newswire","published_at":"2026-05-28T13:15:00.804Z","article_body":"Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration\n\nPR Newswire\n\nSACRAMENTO, Calif. and SAN DIEGO, May 28, 2026\n\nCollaboration integrates AI discovery, human brain organoid modeling, and in\nvivo validation to generate differentiated neurology assets for pharmaceutical\npartnering and development\n\nSACRAMENTO, Calif. and SAN DIEGO, May 28, 2026 /PRNewswire/ -- Lunai Bioworks'\n(NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm\nTherapeutics today announced a strategic collaboration and Letter of Intent\n(LOI) to jointly discover, validate, and advance novel therapeutic targets for\nneurological diseases. The collaboration is supported by a newly awarded grant\nfrom the LouLou Foundation.\n\n(https://mma.prnewswire.com/media/2989184/LUNAI_BIOWORKS_INC__Collaboration.html)\n\nThe collaboration combines BioSymetrics' AI-driven target discovery and in\nvivo zebrafish validation platform with BrainStorm Therapeutics' proprietary\nhuman-derived organoid systems to create an integrated translational engine\nfor neurology drug discovery. The companies intend to generate high-confidence\ntherapeutic programs designed for pharmaceutical partnering, licensing, and\ndownstream development.\n\nThe collaboration is aligned with emerging FDA guidance encouraging adoption\nof innovative new approach methodologies (NAMs) that improve human\ntranslational relevance and reduce dependence on traditional mammalian animal\nmodels in drug development. Initial efforts will focus on rare genetic\nepilepsies and neurodegenerative diseases, including Parkinson's disease.\n\nAs part of the collaboration, the companies are integrating BrainStorm's\nParkinson's disease midbrain organoid foundation model with BioSymetrics'\nproprietary analysis of the Parkinson's Progression Markers Initiative (PPMI)\ndataset, to identify progression-associated biomarkers and high-confidence\ntherapeutically actionable targets. The program is intended to support\nprecision medicine strategies and accelerate the development of differentiated\nCNS therapeutics.\n\nIn a flagship program under the collaboration, BioSymetrics and Brainstorm\nTherapeutics, together with Dr. Calum MacRae at Brigham and Women's Hospital\nand Harvard Medical School, have received funding from the LouLou Foundation\nto identify and advance novel therapeutic approaches for a rare genetic\nepilepsy. The initiative is expected to generate mechanistic insights,\nbiological validation data, and development-stage assets while establishing a\nscalable framework for future neurology programs.\n\nConcurrently, the companies have entered into a Letter of Intent to expand the\ncollaboration across additional neurological indications. The LOI outlines a\nstructured framework to:\n\n * ⁠Identify and prioritize therapeutic targets using integrated computational,\norganoid, and in vivo discovery approaches\n * ⁠Rapidly validate targets across complementary biological systems\n * Advance differentiated programs supported by mechanistic rationale and\ntranslational validation data\n * ⁠Engage pharmaceutical partners, strategic collaborators, and investors\naround selected development opportunities\nThe collaboration is designed to efficiently progress programs from discovery\nthrough translational validation and external partnering, with the goal of\ncreating multiple value-generating opportunities across the neurology\npipeline.\n\n\"Neurological diseases remain one of the largest areas of unmet medical need,\nyet CNS drug development continues to suffer from high rates of clinical trial\nfailure due to poor target selection and limited translational predictability\"\nsaid Dr. Robert Fremeau, Founder & CEO of BrainStorm Therapeutics. \"By\ncombining human-relevant organoid biology with AI-driven discovery and rapid\nin vivo validation, we believe this collaboration can generate\nhigher-confidence therapeutic programs with stronger development and\npartnering potential.\"\n\n\"We believe the combination of AI, organoids, and in vivo validation creates a\nscalable framework for generating high-value neurology programs,\" said David\nWeinstein, Lunai's CEO. \"Our focus is not simply discovery but efficiently\nadvancing targets toward pharmaceutical partnering and downstream clinical\ndevelopment.\"\n\nNeurological diseases represent one of the fastest-growing areas of global\nhealthcare burden, yet drug development success rates remain among the lowest\nin the industry. The companies believe that integrating computational\ndiscovery with human-relevant biology and rapid functional validation may\nimprove translational success while creating multiple pathways for value\ncreation, including strategic partnerships, joint ventures, licensing\ntransactions, and asset-centric financings.\n\nThe collaboration is intended to generate a portfolio of discrete,\ndevelopment-ready neurology programs that may be advanced through a range of\nstructures, including licensing agreements, co-development partnerships,\nspecial purpose vehicles, and new company formation. By focusing on\nbiologically validated targets with defined translational pathways, the\ncompanies aim to accelerate timelines to partnering and unlock additional\nopportunities for non-dilutive funding.\n\nAbout Lunai Bioworks\nLunai Bioworks (NASDAQ: LNAI) is an AI-driven biotechnology company focused on\naccelerating drug discovery and development across the central nervous system\n(CNS) and other high-unmet-need areas. Lunai integrates data analytics and\nexperimental biology to improve development efficiency, reduce cost, and\nincrease the probability of success. For more visit https://lunaibioworks.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4698122-1&h=902069016&u=https%3A%2F%2Flunaibioworks.com%2F&a=https%3A%2F%2Flunaibioworks.com)\n.\n\nAbout BrainStorm Therapeutics\nBrainStorm Therapeutics is a precision neuroscience company focused on\ndeveloping innovative therapies for neurological disorders using advanced\nhuman-relevant model systems, translational biology, and artificial\nintelligence–driven discovery approaches. The company leverages proprietary\norganoid platforms, computational biology, and disease biology insights to\nsupport therapeutic discovery, target validation, and therapeutic\ndevelopment. For more visit https://brainstormtherapeutics.org\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4698122-1&h=1963293362&u=https%3A%2F%2Fbrainstormtherapeutics.org%2F&a=https%3A%2F%2Fbrainstormtherapeutics.org)\n.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nregarding the expected scope, objectives, and potential benefits of the\ncollaboration, the ability to generate and validate therapeutic targets, and\nthe potential for future partnerships, financings, or development programs.\nThese statements are based on current expectations and involve risks and\nuncertainties that may cause actual results to differ materially.\n\nFactors that could affect outcomes include the parties' ability to generate\nand validate data, advance programs, enter into definitive agreements, secure\npartnerships or funding, and achieve regulatory milestones. The companies\nundertake no obligation to update forward-looking statements except as\nrequired by law.\n\n(https://mma.prnewswire.com/media/2814530/Lunai_Logo.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-and-brainstorm-therapeutics-launch-foundation-funded-parkinsons-and-rare-epilepsy-ai-discovery-collaboration-302784369.html\n(https://www.prnewswire.com/news-releases/lunai-bioworks-and-brainstorm-therapeutics-launch-foundation-funded-parkinsons-and-rare-epilepsy-ai-discovery-collaboration-302784369.html)\n\nSOURCE Lunai Bioworks Inc.\n\n\n\nir@lunaibioworks.com, http://www.lunaibioworks.com/\n\nPhoto: \nhttps://mma.prnewswire.com/media/2989184/LUNAI_BIOWORKS_INC__Collaboration.jpg\nhttps://mma.prnewswire.com/media/2814530/Lunai_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbrCJzVa","title":"Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration","author":"PR Newswire","ticker":"LNAI","created":"2026-05-28T13:15:00.804Z","tickers":["LNAI"],"exchange":"NASDAQ","article_body":"Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration\n\nPR Newswire\n\nSACRAMENTO, Calif. and SAN DIEGO, May 28, 2026\n\nCollaboration integrates AI discovery, human brain organoid modeling, and in\nvivo validation to generate differentiated neurology assets for pharmaceutical\npartnering and development\n\nSACRAMENTO, Calif. and SAN DIEGO, May 28, 2026 /PRNewswire/ -- Lunai Bioworks'\n(NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm\nTherapeutics today announced a strategic collaboration and Letter of Intent\n(LOI) to jointly discover, validate, and advance novel therapeutic targets for\nneurological diseases. The collaboration is supported by a newly awarded grant\nfrom the LouLou Foundation.\n\n(https://mma.prnewswire.com/media/2989184/LUNAI_BIOWORKS_INC__Collaboration.html)\n\nThe collaboration combines BioSymetrics' AI-driven target discovery and in\nvivo zebrafish validation platform with BrainStorm Therapeutics' proprietary\nhuman-derived organoid systems to create an integrated translational engine\nfor neurology drug discovery. The companies intend to generate high-confidence\ntherapeutic programs designed for pharmaceutical partnering, licensing, and\ndownstream development.\n\nThe collaboration is aligned with emerging FDA guidance encouraging adoption\nof innovative new approach methodologies (NAMs) that improve human\ntranslational relevance and reduce dependence on traditional mammalian animal\nmodels in drug development. Initial efforts will focus on rare genetic\nepilepsies and neurodegenerative diseases, including Parkinson's disease.\n\nAs part of the collaboration, the companies are integrating BrainStorm's\nParkinson's disease midbrain organoid foundation model with BioSymetrics'\nproprietary analysis of the Parkinson's Progression Markers Initiative (PPMI)\ndataset, to identify progression-associated biomarkers and high-confidence\ntherapeutically actionable targets. The program is intended to support\nprecision medicine strategies and accelerate the development of differentiated\nCNS therapeutics.\n\nIn a flagship program under the collaboration, BioSymetrics and Brainstorm\nTherapeutics, together with Dr. Calum MacRae at Brigham and Women's Hospital\nand Harvard Medical School, have received funding from the LouLou Foundation\nto identify and advance novel therapeutic approaches for a rare genetic\nepilepsy. The initiative is expected to generate mechanistic insights,\nbiological validation data, and development-stage assets while establishing a\nscalable framework for future neurology programs.\n\nConcurrently, the companies have entered into a Letter of Intent to expand the\ncollaboration across additional neurological indications. The LOI outlines a\nstructured framework to:\n\n * ⁠Identify and prioritize therapeutic targets using integrated computational,\norganoid, and in vivo discovery approaches\n * ⁠Rapidly validate targets across complementary biological systems\n * Advance differentiated programs supported by mechanistic rationale and\ntranslational validation data\n * ⁠Engage pharmaceutical partners, strategic collaborators, and investors\naround selected development opportunities\nThe collaboration is designed to efficiently progress programs from discovery\nthrough translational validation and external partnering, with the goal of\ncreating multiple value-generating opportunities across the neurology\npipeline.\n\n\"Neurological diseases remain one of the largest areas of unmet medical need,\nyet CNS drug development continues to suffer from high rates of clinical trial\nfailure due to poor target selection and limited translational predictability\"\nsaid Dr. Robert Fremeau, Founder & CEO of BrainStorm Therapeutics. \"By\ncombining human-relevant organoid biology with AI-driven discovery and rapid\nin vivo validation, we believe this collaboration can generate\nhigher-confidence therapeutic programs with stronger development and\npartnering potential.\"\n\n\"We believe the combination of AI, organoids, and in vivo validation creates a\nscalable framework for generating high-value neurology programs,\" said David\nWeinstein, Lunai's CEO. \"Our focus is not simply discovery but efficiently\nadvancing targets toward pharmaceutical partnering and downstream clinical\ndevelopment.\"\n\nNeurological diseases represent one of the fastest-growing areas of global\nhealthcare burden, yet drug development success rates remain among the lowest\nin the industry. The companies believe that integrating computational\ndiscovery with human-relevant biology and rapid functional validation may\nimprove translational success while creating multiple pathways for value\ncreation, including strategic partnerships, joint ventures, licensing\ntransactions, and asset-centric financings.\n\nThe collaboration is intended to generate a portfolio of discrete,\ndevelopment-ready neurology programs that may be advanced through a range of\nstructures, including licensing agreements, co-development partnerships,\nspecial purpose vehicles, and new company formation. By focusing on\nbiologically validated targets with defined translational pathways, the\ncompanies aim to accelerate timelines to partnering and unlock additional\nopportunities for non-dilutive funding.\n\nAbout Lunai Bioworks\nLunai Bioworks (NASDAQ: LNAI) is an AI-driven biotechnology company focused on\naccelerating drug discovery and development across the central nervous system\n(CNS) and other high-unmet-need areas. Lunai integrates data analytics and\nexperimental biology to improve development efficiency, reduce cost, and\nincrease the probability of success. For more visit https://lunaibioworks.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4698122-1&h=902069016&u=https%3A%2F%2Flunaibioworks.com%2F&a=https%3A%2F%2Flunaibioworks.com)\n.\n\nAbout BrainStorm Therapeutics\nBrainStorm Therapeutics is a precision neuroscience company focused on\ndeveloping innovative therapies for neurological disorders using advanced\nhuman-relevant model systems, translational biology, and artificial\nintelligence–driven discovery approaches. The company leverages proprietary\norganoid platforms, computational biology, and disease biology insights to\nsupport therapeutic discovery, target validation, and therapeutic\ndevelopment. For more visit https://brainstormtherapeutics.org\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4698122-1&h=1963293362&u=https%3A%2F%2Fbrainstormtherapeutics.org%2F&a=https%3A%2F%2Fbrainstormtherapeutics.org)\n.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nregarding the expected scope, objectives, and potential benefits of the\ncollaboration, the ability to generate and validate therapeutic targets, and\nthe potential for future partnerships, financings, or development programs.\nThese statements are based on current expectations and involve risks and\nuncertainties that may cause actual results to differ materially.\n\nFactors that could affect outcomes include the parties' ability to generate\nand validate data, advance programs, enter into definitive agreements, secure\npartnerships or funding, and achieve regulatory milestones. The companies\nundertake no obligation to update forward-looking statements except as\nrequired by law.\n\n(https://mma.prnewswire.com/media/2814530/Lunai_Logo.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-and-brainstorm-therapeutics-launch-foundation-funded-parkinsons-and-rare-epilepsy-ai-discovery-collaboration-302784369.html\n(https://www.prnewswire.com/news-releases/lunai-bioworks-and-brainstorm-therapeutics-launch-foundation-funded-parkinsons-and-rare-epilepsy-ai-discovery-collaboration-302784369.html)\n\nSOURCE Lunai Bioworks Inc.\n\n\n\nir@lunaibioworks.com, http://www.lunaibioworks.com/\n\nPhoto: \nhttps://mma.prnewswire.com/media/2989184/LUNAI_BIOWORKS_INC__Collaboration.jpg\nhttps://mma.prnewswire.com/media/2814530/Lunai_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-28T13:15:00.856802291Z","server_sent_at_ms":1779974100856},"received_at":"2026-05-28T13:15:00.936Z","source_url":"https://www.prnewswire.com/news-releases/lunai-bioworks-and-brainstorm-therapeutics-launch-foundation-funded-parkinsons-and-rare-epilepsy-ai-discovery-collaboration-302784369.html"},"analysis":{"id":"37620","press_release_id":"48187","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Lunai Bioworks and BrainStorm Therapeutics announced a strategic collaboration and Letter of Intent to jointly discover therapeutic targets for neurological diseases, supported by a grant from the LouLou Foundation.\n\nThe partnership integrates Lunai’s AI-driven discovery and zebrafish validation with BrainStorm’s human-derived organoid systems, focusing initially on Parkinson’s disease and rare genetic epilepsies.\n\nThe companies aim to generate high-confidence, development-ready assets for pharmaceutical partnering and licensing, leveraging non-dilutive foundation funding to advance early-stage programs.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"LNAI partners with BrainStorm on AI/organoid neurology discovery; non-dilutive foundation funding validates platform utility."},"keyFigures":{"customDimensions":{"focus_areas":"Parkinson's disease, rare genetic epilepsies","funding_source":"LouLou Foundation grant"}},"quotedText":"We believe the combination of AI, organoids, and in vivo validation creates a scalable framework for generating high-value neurology programs","namedEntities":{"people":[{"name":"Dr. Robert Fremeau","role":"Founder & CEO of BrainStorm Therapeutics"},{"name":"David Weinstein","role":"CEO of Lunai Bioworks"},{"name":"Dr. Calum MacRae","role":"Brigham and Women's Hospital and Harvard Medical School"}],"products":[],"companies":[{"name":"Lunai Bioworks","ticker":"LNAI","relationship":"filer"},{"name":"BioSymetrics","relationship":"subsidiary of Lunai Bioworks"},{"name":"BrainStorm Therapeutics","relationship":"partner"},{"name":"LouLou Foundation","relationship":"funder"},{"name":"Brigham and Women's Hospital","relationship":"academic collaborator"},{"name":"Harvard Medical School","relationship":"academic collaborator"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Strategic collaboration and Letter of Intent (LOI) for early-stage discovery. No definitive commercial agreement, no immediate revenue, and funding is grant-based (non-dilutive). Validates the company's AI/organoid platform but remains pre-clinical."},"tickerRelevance":{"others":[{"ticker":"BSTC","relevance":"partner"}],"primary":"LNAI"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"early-stage partnership","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Lunai Bioworks and BrainStorm Therapeutics announced a strategic collaboration and Letter of Intent to jointly discover therapeutic targets for neurological diseases, supported by a grant from the LouLou Foundation.\n\nThe partnership integrates Lunai’s AI-driven discovery and zebrafish validation with BrainStorm’s human-derived organoid systems, focusing initially on Parkinson’s disease and rare genetic epilepsies.\n\nThe companies aim to generate high-confidence, development-ready assets for pharmaceutical partnering and licensing, leveraging non-dilutive foundation funding to advance early-stage programs.","key_figures":{"customDimensions":{"focus_areas":"Parkinson's disease, rare genetic epilepsies","funding_source":"LouLou Foundation grant"}},"named_entities":{"people":[{"name":"Dr. Robert Fremeau","role":"Founder & CEO of BrainStorm Therapeutics"},{"name":"David Weinstein","role":"CEO of Lunai Bioworks"},{"name":"Dr. Calum MacRae","role":"Brigham and Women's Hospital and Harvard Medical School"}],"products":[],"companies":[{"name":"Lunai Bioworks","ticker":"LNAI","relationship":"filer"},{"name":"BioSymetrics","relationship":"subsidiary of Lunai Bioworks"},{"name":"BrainStorm Therapeutics","relationship":"partner"},{"name":"LouLou Foundation","relationship":"funder"},{"name":"Brigham and Women's Hospital","relationship":"academic collaborator"},{"name":"Harvard Medical School","relationship":"academic collaborator"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-28T13:25:59.052Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"early-stage partnership","sectorWeight":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"durationMs":50693,"modelName":"george-droid-qwen-72b"}}